The companies signed a deal in which Blackstone will provide funding to advance obe-cel, a CD19 CAR T-cell investigational therapy candidate, as well as next-generation product therapies of obe-cel in B-cell malignancies.

As part of the $250 million transaction, Blackstone will invest $150 million in product financing to support obe-cel development and commercialization, with $50 million payable upon closing of the transaction and the remainder payable based on certain development and regulatory achievements.

Blackstone has also agreed to purchase $100 million of Autolus' American depositary shares in a private placement. Blackstone can nominate a member to Autolus' board of directors.

Autolus, Moderna ink license agreement
Biopharmaceutical company Autolus Therapeutics has granted Moderna exclusive license to develop and market mRNA therapeutics that include Autolus' binding...

Blackstone, Intellia, Cellex to launch company addressing limitations of cell therapies
Blackstone Life Sciences has committed $250 million toward the launch of a new autologous and allogeneic universal chimeric antigen receptor T-cell...